How PD-L1 inside cancer cells helps tumors hide from the immune system
PD-L1 Intracellular RNA binding function regulates immune suppression
Researchers are looking at how a protein called PD-L1 inside triple-negative breast cancer cells helps the tumor escape immune attack.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11142972 on NIH RePORTER |
What this research studies
From a patient's perspective, the team will study a newly discovered function of PD-L1 that binds and stabilizes certain RNAs inside tumor cells. They will examine tumor samples and use lab-grown cancer cells and animal models to see how this intracellular PD-L1 affects regulatory immune cells and responses to PD-L1 antibody treatments. The work focuses on triple-negative breast cancer and includes experiments to understand PD-L1's control of RNAs like Foxp1 that support immune suppression. Findings could point to new ways to make immunotherapy work better for patients who now do not respond well.
Who could benefit from this research
Good fit: Patients with triple-negative breast cancer who can contribute tumor tissue (for example during biopsy or surgery) are the most relevant participants for this work.
Not a fit: Patients without triple-negative breast cancer or those seeking an immediate change in clinical treatment are unlikely to receive direct benefit from this laboratory-focused project.
Why it matters
Potential benefit: If successful, this work could explain why some tumors resist PD-L1/PD-1 therapies and suggest new targets to improve immunotherapy for triple-negative breast cancer patients.
How similar studies have performed: Blocking PD-L1 at the cell surface with antibodies has helped some cancer patients, but the concept that PD-L1 binds RNAs inside cells is a novel idea that has not yet been widely tested in people.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Mutter, Robert W — Mayo Clinic Rochester
- Study coordinator: Mutter, Robert W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.